Özet:

The period of pregnancy is a period of physiological, mental and social changes in the life of a woman. These changes during and after pregnancy can cause various mental illnesses. These diseases are common in postpartum depression. Postpartum depression is a major cause of morbidity and mortality for the mother and baby. A major depressive episode that begins with peripartum is defined as postpartum depression when it occurs during pregnancy or up to 4 weeks after childbirth. The frequency is extremely high. It is that biological, psychological and socio-cultural factors are effective in the ethology. It is present with major depression symptoms such as depression, anhedony, guilt thoughts, nervousness, concentration disorder, psychomotor agitation, psychomotor retardation, sleep irregularity, appetite and weight changes. There are many different options for treatment. Most of these options are adapted from major depression treatment. In treatment, serotonin recovery inhibitors (SSRIs), serotonin noradrenaline recovery inhibitors (SNRIs), tricyctic antidepressants, estradiol, progesterone, psychotherapies, electronvulsive therapy and brexanolone can be used. Brexanolone is a new medication that promises hope in the treatment of postpartum depression. It is the only treatment that has received specific indications for postpartum depression. This aggregation study aims to study new developments in the etiology, diagnosis and treatment of postpartum depression in the light of current data.

Anahtar Kelimeler: